Validation Study of the Korean Version of the EORTC QLQ-HDC29
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Reliability and validity of the Korean version of the EORTC HDC-29 [ Time Frame: at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT) ]
Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency.
Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who are diagnosed with hematologic malignancies and who are planned to recieve high-dose chemotherapy followed by allo or auto stem cell transplantation in Seoul National University Hospital, Korea
Patients who are aged more than 18 years
Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT)
Patients who agree with the informed consent
Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity